---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-257298"
form_type: "8-K/A"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:21:16.279003+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports positive WVE-007 target engagement: up to 85% Activin E reduction; WVE-008 candidate selected

## Summary
- WVE-007 Activin E reductions: 85% (400mg), 75% (240mg), 56% (75mg) at day 29; Cohort 1 durable through 6 months, supporting 1-2x/year dosing.
- WVE-007 safe/well-tolerated; DMC cleared dose expansion to 600mg and beyond. Body composition/weight data updates expected starting 4Q2025.
- WVE-008 selected as PNPLA3-I148M RNA editing candidate for liver disease; CTA filing expected in 2026. Estimated 9M homozygous patients in US/EU.
- WVE-006 AATD cohort 3 (600mg) now underway; previously restored 13 µM total AAT with 64% M-AAT. Multidose data expected 1Q2026.
- Platform data: single oligonucleotide can simultaneously edit and silence two targets (LDLR up, PCSK9 down) in preclinical models.

## SEC filing metadata
- accession: 0001193125-25-257298
- form_type: 8-K/A
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525257298/0001193125-25-257298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525257298/d59691d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-257298
- JSON: https://secwatch.observer/filing/0001193125-25-257298.json
- Plain text: https://secwatch.observer/filing/0001193125-25-257298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.